Nkarta, Inc. Additional Paid in Capital, Common Stock
Nkarta, Inc. (NKTX) had Additional Paid in Capital, Common Stock of $964.66 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-10
- 2026-06-30: Additional Paid in Capital, Common Stock $964.66M.
- 2026-03-31: Additional Paid in Capital, Common Stock $962.12M.
- 2025-12-31: Additional Paid in Capital, Common Stock $960.22M.
- 2025-09-30: Additional Paid in Capital, Common Stock $958.26M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $964.66M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $962.12M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $960.22M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $958.26M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $956.48M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $954.35M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $951.52M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $947.44M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $943.38M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $938.72M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $708.71M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $704.90M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $700.61M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $695.56M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $690.81M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $685.93M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $678.97M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $459.39M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $455.21M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $451.32M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $447.30M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $443.35M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $439.24M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $435.10M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $2.54M 10-Q · filed 2020-08-20 | |
| 2019-12-31 | $1.18M 10-K · filed 2021-03-25 | $1.18M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |